E45 owner Karo Healthcare has named Sue Egstrand CEO to ‘scale the business across markets’.
Egstrand will assume the role on 1 January 2027, leading Karo into its “next phase of growth” as it makes a play to become a top five consumer health care player in Europe.
She succeeds Christoffer Lorenzen and joins from private equity-backed animal health business Dechra, where she was President, Europe and International, and CCO.
Egstrand has also held roles across a number of international health care and consumer businesses, including Pfizer, GSK and Reckitt.
“We are delighted to appoint Egstrand as Karo’s next CEO,” said Hans Arstad, Partner at KKR and Chair of the Board of Karo Healthcare.
“Karo has built a strong European consumer health care platform, with significant opportunities for further growth.
“Egstrand brings the right combination of consumer health care experience and international leadership expertise to build on Karo’s achievements to date, strengthen its commercial momentum and scale the business across markets.
“We are confident Egstrand is the right leader to help Karo realise its considerable future potential.”
Karo Healthcare’s portfolio includes specialist skin health brands E45, Locobase, Decubal and Apobase.
Commenting on her appointment, Egstrand added: “I am excited to join Karo at an important stage in the company’s development.
“Karo has built a strong portfolio of trusted brands, an international presence and significant
opportunities ahead.
“I look forward to working with the team across Karo to build on this foundation, strengthen the company’s commercial capabilities and support its continued growth.”
Related content:
- Exclusive: Estée Lauder Companies’ Senior VP & General Manager, UK & Ireland, steps down
- Neom Wellbeing CEO Isabel Malbois exits the business after five years
- Estée Lauder Companies Global President Justin Boxford exits the business
- Patrick Ta Beauty shakes up leadership team with CMO and Creative VP appointments